Final answer:
Iclusig (ponatinib) is the tyrosine kinase inhibitor that has a black box warning for arterial thrombosis, indicating a serious risk of arterial occlusion events.
Step-by-step explanation:
The tyrosine kinase inhibitor with a black box warning for arterial thrombosis is Iclusig (ponatinib). While other tyrosine kinase inhibitors such as Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib), and Tasigna (nilotinib) are used to treat various types of cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), it is Iclusig that carries this specific serious warning due to the increased risk of arterial occlusion that can lead to strokes, heart attacks, and the obstruction of blood vessels in the extremities which may require amputation.